A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion

Muayad Almahariq, Tamara Tsalkova, Fang C. Mei, Haijun Chen, Jia Zhou, Sarita K. Sastry, Frank Schwede, Xiaodong Cheng

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP. Identifying pharmacological probes for selectively modulating EPAC activity represents a significant unmet need within the research field. Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazono]-3-oxo- propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. Using this novel EPAC-specific inhibitor, we have probed the functional roles of overexpression of EPAC1 in pancreatic cancer cells. Our studies show that EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)122-128
Number of pages7
JournalMolecular Pharmacology
Volume83
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Pancreatic Neoplasms
Cell Movement
Proteins
Second Messenger Systems
Cyclic AMP-Dependent Protein Kinases
Nucleotides
Phosphorylation
Pharmacology
Insulin
Research

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Almahariq, M., Tsalkova, T., Mei, F. C., Chen, H., Zhou, J., Sastry, S. K., ... Cheng, X. (2013). A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Molecular Pharmacology, 83(1), 122-128. https://doi.org/10.1124/mol.112.080689

A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. / Almahariq, Muayad; Tsalkova, Tamara; Mei, Fang C.; Chen, Haijun; Zhou, Jia; Sastry, Sarita K.; Schwede, Frank; Cheng, Xiaodong.

In: Molecular Pharmacology, Vol. 83, No. 1, 01.2013, p. 122-128.

Research output: Contribution to journalArticle

Almahariq, M, Tsalkova, T, Mei, FC, Chen, H, Zhou, J, Sastry, SK, Schwede, F & Cheng, X 2013, 'A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion', Molecular Pharmacology, vol. 83, no. 1, pp. 122-128. https://doi.org/10.1124/mol.112.080689
Almahariq, Muayad ; Tsalkova, Tamara ; Mei, Fang C. ; Chen, Haijun ; Zhou, Jia ; Sastry, Sarita K. ; Schwede, Frank ; Cheng, Xiaodong. / A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. In: Molecular Pharmacology. 2013 ; Vol. 83, No. 1. pp. 122-128.
@article{5db8f2d30b1f4347b36e0d17e163e199,
title = "A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion",
abstract = "Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP. Identifying pharmacological probes for selectively modulating EPAC activity represents a significant unmet need within the research field. Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazono]-3-oxo- propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. Using this novel EPAC-specific inhibitor, we have probed the functional roles of overexpression of EPAC1 in pancreatic cancer cells. Our studies show that EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.",
author = "Muayad Almahariq and Tamara Tsalkova and Mei, {Fang C.} and Haijun Chen and Jia Zhou and Sastry, {Sarita K.} and Frank Schwede and Xiaodong Cheng",
year = "2013",
month = "1",
doi = "10.1124/mol.112.080689",
language = "English (US)",
volume = "83",
pages = "122--128",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion

AU - Almahariq, Muayad

AU - Tsalkova, Tamara

AU - Mei, Fang C.

AU - Chen, Haijun

AU - Zhou, Jia

AU - Sastry, Sarita K.

AU - Schwede, Frank

AU - Cheng, Xiaodong

PY - 2013/1

Y1 - 2013/1

N2 - Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP. Identifying pharmacological probes for selectively modulating EPAC activity represents a significant unmet need within the research field. Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazono]-3-oxo- propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. Using this novel EPAC-specific inhibitor, we have probed the functional roles of overexpression of EPAC1 in pancreatic cancer cells. Our studies show that EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.

AB - Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP. Identifying pharmacological probes for selectively modulating EPAC activity represents a significant unmet need within the research field. Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazono]-3-oxo- propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. Using this novel EPAC-specific inhibitor, we have probed the functional roles of overexpression of EPAC1 in pancreatic cancer cells. Our studies show that EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84871563190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871563190&partnerID=8YFLogxK

U2 - 10.1124/mol.112.080689

DO - 10.1124/mol.112.080689

M3 - Article

VL - 83

SP - 122

EP - 128

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 1

ER -